Translation. Region: Russian Federation –
Source: People's Republic of China in Russian – People's Republic of China in Russian –
An important disclaimer is at the bottom of this article.
Source: People's Republic of China – State Council News
BEIJING, October 26 (Xinhua) — AstraZeneca's new global research and development center was officially opened Saturday at the Biopark of the Beijing Development Area (BDA). This is the British pharmaceutical giant's sixth global strategic research and development center and its second in China, following its first in Shanghai.
The new institution will leverage Beijing's scientific ecosystem and the strengths of artificial intelligence to accelerate the development of innovative next-generation medicines. It will collaborate closely with the Shanghai-based Global Strategic Research Center to lead drug discovery and clinical development, accelerating the implementation of drug innovations.
"The development of new medicines is a key driver of the pharmaceutical industry. We strive to leverage the strengths of our ecosystem partners through collaboration, achieving powerful synergies," said He Jing, AstraZeneca's Senior Vice President and Head of Global R&D in China.
She noted that the Beijing center will benefit from BDA's support, facilities, and robust research ecosystem, expanding its collaboration with research hospitals, universities, and biotechnology companies.
The BDA is a key hub for high-tech industries and the biomedical sector, home to over 5,000 biopharmaceutical companies, including global firms such as Pfizer, Bayer, and Sanofi, as well as local players such as Beijing Tide Pharmaceutical Co., Ltd. and Youcare Pharmaceutical Group, covering the entire spectrum of the pharmaceutical and medical sectors. Since 2025, two innovative drugs and three innovative medical devices have been approved for market launch here.
Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.